EARLY BREAST CANCER
Clinical trials for EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hope for young breast cancer survivors: study tests pausing treatment for pregnancy
Disease control OngoingThis study looks at whether young women with early-stage, hormone-sensitive breast cancer can safely pause their hormone therapy for up to two years to try to get pregnant. It involves 518 women aged 18 to 42 who have already been on hormone therapy for at least 18 months. The go…
Matched conditions: EARLY BREAST CANCER
Phase: NA • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
Could a Chemo-Free combo beat early breast cancer?
Disease control OngoingThis study tests whether a chemotherapy-free combination of drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer. About 393 participants will receive these drugs to see if the cancer disappears completely. The goal is to avoid chemoth…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
Could a gentler chemo work just as well for some breast cancers?
Disease control OngoingThis study tests a less intense chemotherapy combination for people with early-stage HER2-positive breast cancer. The goal is to see if a milder regimen (paclitaxel, trastuzumab, and pertuzumab) can clear the cancer before surgery as effectively as the standard stronger regimen, …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
Promising drug combo aims to stop early breast cancer recurrence
Disease control OngoingThis large phase 3 trial is testing whether adding the drug ribociclib to standard hormone therapy can help prevent breast cancer from returning in people with hormone receptor-positive, HER2-negative early breast cancer. Over 5,000 women and men are participating. The study comp…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New breast cancer drug tested against standard treatment in phase 3 trial
Disease control TerminatedThis study compares a new drug called EG1206A to the approved drug Perjeta, both given with trastuzumab and chemotherapy, for people with HER2-positive early breast cancer. The treatment is given before and after surgery to see if the new drug works as well as the standard one. T…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: EirGenix, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New pill aims to keep early breast cancer from returning
Disease control OngoingThis study tests a new drug called giredestrant against standard hormone therapies in over 4,000 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at stopping the cancer from coming back. Participants take the drug daily for se…
Matched conditions: EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Could a pill replace chemo for some breast cancers?
Disease control OngoingThis study tests whether a combination of two pills (letrozole and abemaciclib) works as well as standard chemotherapy before surgery for women with a common type of early breast cancer (HR-positive, HER2-negative). About 200 women with high or intermediate risk will be randomly …
Matched conditions: EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
AI reads old slides to predict breast cancer return
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back. Researchers will analyze stored tumor slides from 2,200 women who had ER-positive, HER2-negative breast cancer. The AI's predictions will be com…
Matched conditions: EARLY BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC